Tirzepatide for Obesity
(GLOW Trial)

Recruiting in Palo Alto (17 mi)

Overseen byDenise Houston, PhD

Age: 65+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase 4

Waitlist Available

Sponsor: Wake Forest University Health Sciences

No Placebo Group

Prior Safety Data

Trial Summary

What is the purpose of this trial?

The goal of this study is to examine how tirzepatide affects body composition, bone health, and physical performance in older adults over a nine-month period. Participants will take tirzepatide weekly, have clinic visits every 4 weeks, meet study doctor and registered dietitian every 4 weeks in person or video conference, attend group intervention sessions twice a month via video conference, weigh daily with a study-provided smart scale, keep a record of all foods and beverages consumed, and use a study-provided activity tracker to keep track of daily step counts.

Eligibility Criteria

This trial is for older adults with obesity. Participants must be willing to take tirzepatide weekly, attend regular clinic visits and virtual meetings, use a smart scale daily, record their food and beverage intake, and monitor steps with an activity tracker.

Inclusion Criteria

Community dwelling

I can arrange my own travel for study visits.

Willing to provide informed consent

See 4 more

Exclusion Criteria

Vegan or other severe dietary restriction

My liver is not functioning properly or I have liver disease.

History of mild cognitive impairment or dementia or cognitive impairment on Montreal Cognitive Assessment (MoCA score <22)

See 28 more

Treatment Details

Interventions

Tirzepatide (GLP-1 Receptor Agonist)

Trial OverviewThe study tests the effects of tirzepatide on body composition, bone health, and physical performance over nine months. It involves frequent check-ins with healthcare professionals and group sessions via video conference.

Participant Groups

1Treatment groups

Experimental Treatment

Group I: TirzepatideExperimental Treatment1 Intervention

Tirzepatide injection once weekly for 9 months